Pfizer Seen Holding Strategic Edge in Bidding Battle for Metsera

Pfizer is perceived to hold a potential “trump card” in its pursuit of U.S. biotech Metsera, giving it leverage in the rapidly intensifying bidding war with Novo Nordisk. Industry analysts suggest Pfizer’s position is strengthened by its sizeable obesity-pipeline ambitions and existing metabolic research assets, which could create greater synergies with Metsera’s early-stage weight-loss candidates. While Novo Nordisk has aggressively expanded through acquisitions to protect its leadership in the GLP-1 category, Pfizer’s interest indicates a strategic attempt to rebuild momentum after setbacks to its own obesity programme. The acquisition battle underscores the value attached to next-generation metabolic therapies, particularly multi-agonist drug platforms expected to define the sector’s second innovation wave.